Fintel reports that on April 4, 2025, Argus Research downgraded their outlook for Biogen (NasdaqGS:BIIB) from Buy to Hold.

Biogen Inc. (NASDAQ:BIIB – Get Free Report) has been given a consensus rating of “Hold” by the thirty-one brokerages that are ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Biogen (BIIB – Research Report), with a price target ...

Shares of Biogen Inc. BIIB advanced 5.65% to $120.49 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 9.52% to 5,456.90 and ...

Biogen's $7.22 per share buyout offer signals confidence in Sage's commercial potential and drug pipeline. Read why SAGE ...

Biogen (NASDAQ:BIIB – Get Free Report) was downgraded by Argus from a “buy” rating to a “hold” rating in a report released on ...

Morgan Stanley lowered the firm’s price target on Biogen (BIIB) to $152 from $157 and keeps an Equal Weight rating on the shares. The firm ...

Shares of Biogen Inc. BIIB slipped 4.31% to $114.05 Tuesday, on what proved to be an all-around poor trading session for the ...

Sage Therapeutics faces challenges with a 90% value drop but shows promise with Zurzuvae for postpartum depression. Click ...

Biogen (NasdaqGS:BIIB) recently received Fast Track designation from the FDA for its Alzheimer's therapy, BIIB080, signaling a significant advancement in its drug development ambitions. However, ...

During the last three months, 14 analysts shared their evaluations of Biogen BIIB, revealing diverse outlooks from bullish to bearish. The table below offers a condensed view of their recent ...